Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
13 pending office actions • 4 clients • 13 examiners • 11 art units • 0 of 13 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
DUANE MORRIS LLP - Quest Diagnostics works in Biotechnology & Pharmaceuticals and reports 11 pending office actions. The firm-level profile includes 13370 career applications, giving the client-specific workload a broad portfolio context.
The resolved allowance rate is 87.71%. Allowed matters average 3.37 office actions per allowance, indicating that successful resolution generally follows several examination exchanges. The profile therefore combines a focused current workload with a firm record showing frequent allowance and sustained prosecution effort before allowance.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (23%) |
| §103 only | 7 (54%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
| VANORE, DAVID A | 1 | 88.8% | +7.6% |
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| GERIDO, DWAN A | 1 | 58.1% | +30.4% |
| WALLENHORST, MAUREEN | 1 | 78.9% | +5.9% |
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829111 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI | SHELTON, SYNPHANE LA'SHAWN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 22d overdue |
| 19008056 | MASS SPECTROMETRY ASSAY FOR CONGENITAL ADRENAL HYPERPLASIA | VANORE, DAVID A | — |
| 18288540 | WARNING SYSTEM FOR A DECAPPING/CAPPING SYSTEM | WALLENHORST, MAUREEN | — |
| 17006360 | PATHOGENICITY SCORING SYSTEM FOR HUMAN CLINICAL GENETICS | HAYES, JONATHAN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17986339 | BORDETELLA DETECTION ASSAY | BERTAGNA, ANGELA MARIE | 20d |
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | FRITCHMAN, REBECCA M | — |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | SINGH, SATYENDRA K | — |
| 18769857 | METHODS FOR DETECTING DIHYDROXYVITAMIN D METABOLITES BY MASS SPECTROMETRY | GERIDO, DWAN A | — |
| 18473600 | ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS | MARCSISIN, ELLEN JEAN | — |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | CHEONG, CHEOM-GIL | — |
| 17588925 | Lp-PLA2 ASSAYS AND COMPOSITION WITH DETERGENT | MARTIN, PAUL C | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Quest Diagnostics | 9 |
| CLEVELAND HEARTLAB, INC. | 2 |
| Quest Diagnostics Investments LLC | 1 |
| Athena Diagnostics | 1 |
| Art Unit | Apps |
|---|---|
| 1797 | 2 |
| 1758 | 1 |
| 1657 | 1 |
| 1652 | 1 |
| 1677 | 1 |
| 1645 | 1 |
| 1681 | 1 |
| 1653 | 1 |
| 1678 | 1 |
| 1682 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | Quest Diagnostics Investments Incorporated | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | — | Pending | Jan 28, 2026 |
| 19008056 | MASS SPECTROMETRY ASSAY FOR CONGENITAL ADRENAL HYPERPLASIA | Quest Diagnostics Investments LLC | VANORE, DAVID A | §101§102Other | Non-Final OA | — | Pending | Jan 02, 2025 | |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | Quest Diagnostics Investments Incorporated | SINGH, SATYENDRA K | 1657 | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18829111 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI | Cleveland Heartlab, Inc. | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18769857 | METHODS FOR DETECTING DIHYDROXYVITAMIN D METABOLITES BY MASS SPECTROMETRY | Quest Diagnostics Investments LLC | GERIDO, DWAN A | 1797 | §103 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18288540 | WARNING SYSTEM FOR A DECAPPING/CAPPING SYSTEM | Quest Diagnostics Investments LLC | WALLENHORST, MAUREEN | 1797 | §102§103§112 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18473600 | ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS | Quest Diagnostics Investments LLC | MARCSISIN, ELLEN JEAN | 1677 | §103Other | Final Rejection | — | Pending | Sep 25, 2023 |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | Quest Diagnostics Investments LLC | CHEONG, CHEOM-GIL | 1645 | §103 | Final Rejection | — | Pending | Jun 29, 2023 |
| 17986339 | BORDETELLA DETECTION ASSAY | Quest Diagnostics Investments LLC | BERTAGNA, ANGELA MARIE | 1681 | §112 | Final Rejection | 20d | Pending | Nov 14, 2022 |
| 17588925 | Lp-PLA2 ASSAYS AND COMPOSITION WITH DETERGENT | Cleveland Heartlab, Inc. | MARTIN, PAUL C | 1653 | §103 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | Quest Diagnostics Investments LLC | IVICH, FERNANDO NMN | 1678 | §101§103 | Non-Final OA | 22d overdue | Pending | Nov 09, 2021 |
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | Quest Diagnostics Investments LLC | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | — | Pending | Mar 15, 2021 |
| 17006360 | PATHOGENICITY SCORING SYSTEM FOR HUMAN CLINICAL GENETICS | Athena Diagnostics, Inc. | HAYES, JONATHAN EDWARD | 1685 | §101§112 | Non-Final OA | — | Pending | Aug 28, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial87.7% of resolved applications prosecuted by Duane Morris LLP - Quest Diagnostics were allowed, across 13,370 applications in USPTO records.
3.37 office actions per allowed application on average.
13 pending office actions as of October 2026, for 4 clients, before 13 examiners in 11 art units.
